Literature DB >> 9861015

Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease.

C Russo1, G Angelini, D Dapino, A Piccini, G Piombo, G Schettini, S Chen, J K Teller, D Zaccheo, P Gambetti, M Tabaton.   

Abstract

We have characterized the interaction between apolipoprotein E (apoE) and amyloid beta peptide (Abeta) in the soluble fraction of the cerebral cortex of Alzheimer's disease (AD) and control subjects. Western blot analysis with specific antibodies identified in both groups a complex composed of the full-length apoE and Abeta peptides ending at residues 40 and 42. The apoE-Abeta soluble aggregate is less stable in AD brains than in controls, when treated with the anionic detergent SDS. The complex is present in significantly higher quantity in control than in AD brains, whereas in the insoluble fraction an inverse correlation has previously been reported. Moreover, in the AD subjects the Abeta bound to apoE is more sensitive to protease digestion than is the unbound Abeta. Taken together, our results indicate that in normal brains apoE efficiently binds and sequesters Abeta, preventing its aggregation. In AD, the impaired apoE-Abeta binding leads to the critical accumulation of Abeta, facilitating plaque formation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9861015      PMCID: PMC28089          DOI: 10.1073/pnas.95.26.15598

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

2.  The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease.

Authors:  R Mayeux; Y Stern; R Ottman; T K Tatemichi; M X Tang; G Maestre; C Ngai; B Tycko; H Ginsberg
Journal:  Ann Neurol       Date:  1993-11       Impact factor: 10.422

Review 3.  Sequestration of amyloid beta-peptide.

Authors:  D Goldgaber; A I Schwarzman; R Bhasin; L Gregori; D Schmechel; A M Saunders; A D Roses; W J Strittmatter
Journal:  Ann N Y Acad Sci       Date:  1993-09-24       Impact factor: 5.691

4.  Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments.

Authors:  J Ma; A Yee; H B Brewer; S Das; H Potter
Journal:  Nature       Date:  1994-11-03       Impact factor: 49.962

5.  Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid.

Authors:  M Tabaton; M G Nunzi; R Xue; M Usiak; L Autilio-Gambetti; P Gambetti
Journal:  Biochem Biophys Res Commun       Date:  1994-05-16       Impact factor: 3.575

6.  Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

Authors:  K Blennow; C Hesse; P Fredman
Journal:  Neuroreport       Date:  1994-12-20       Impact factor: 1.837

7.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

8.  Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.

Authors:  T C Saido; T Iwatsubo; D M Mann; H Shimada; Y Ihara; S Kawashima
Journal:  Neuron       Date:  1995-02       Impact factor: 17.173

9.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.

Authors:  D E Schmechel; A M Saunders; W J Strittmatter; B J Crain; C M Hulette; S H Joo; M A Pericak-Vance; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

10.  Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.

Authors:  K C Evans; E P Berger; C G Cho; K H Weisgraber; P T Lansbury
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

View more
  18 in total

1.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

2.  Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

Authors:  R B DeMattos; K R Bales; D J Cummins; J C Dodart; S M Paul; D M Holtzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  High-density lipoprotein mimetic peptide 4F mitigates amyloid-β-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Suresh K Swaminathan; Karunya K Kandimalla; G William Rebeck; Ling Li
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372

4.  Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4.

Authors:  Tina Bilousova; Mikhail Melnik; Emily Miyoshi; Bianca L Gonzalez; Wayne W Poon; Harry V Vinters; Carol A Miller; Maria M Corrada; Claudia Kawas; Asa Hatami; Ricardo Albay; Charles Glabe; Karen H Gylys
Journal:  Am J Pathol       Date:  2019-05-17       Impact factor: 4.307

5.  Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model.

Authors:  John D Fryer; Kelly Simmons; Maia Parsadanian; Kelly R Bales; Steven M Paul; Patrick M Sullivan; David M Holtzman
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

6.  Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.

Authors:  Leon M Tai; Tina Bilousova; Lisa Jungbauer; Stephen K Roeske; Katherine L Youmans; Chunjiang Yu; Wayne W Poon; Lindsey B Cornwell; Carol A Miller; Harry V Vinters; Linda J Van Eldik; David W Fardo; Steve Estus; Guojun Bu; Karen Hoppens Gylys; Mary Jo Ladu
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

7.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.

Authors:  D M Holtzman; K R Bales; T Tenkova; A M Fagan; M Parsadanian; L J Sartorius; B Mackey; J Olney; D McKeel; D Wozniak; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

Review 8.  Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease.

Authors:  Massimo Tabaton; Alessandra Piccini
Journal:  Int J Exp Pathol       Date:  2005-06       Impact factor: 1.925

Review 9.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

10.  Apolipoprotein E knockout mice have accentuated malnutrition with mucosal disruption and blunted insulin-like growth factor I responses to refeeding.

Authors:  Reinaldo B Oriá; Carlos Meton G Vieira; Relana C Pinkerton; Carlos M de Castro Costa; Maria Beatriz Lopes; Isa Hussaini; Weibin Shi; Gerly A C Brito; Aldo A M Lima; Richard L Guerrant
Journal:  Nutr Res       Date:  2006-08       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.